Ticker > Company >

Suven Pharma share price

Suven Pharmaceuticals Ltd.

NSE: SUVENPHAR BSE: 543064 SECTOR: Pharmaceuticals & Drugs  67k   296   44

1058.10
+3.05 (0.29%)
NSE: Today, 02:14 PM

Price Summary

Today's High

₹ 1068.6

Today's Low

₹ 1049

52 Week High

₹ 1360

52 Week Low

₹ 585.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

26935.52 Cr.

Enterprise Value

26952.51 Cr.

No. of Shares

25.46 Cr.

P/E

108.96

P/B

12.21

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  86.66

CASH

21.58 Cr.

DEBT

38.58 Cr.

Promoter Holding

50.1 %

EPS (TTM)

₹  9.71

Sales Growth

-22.94%

ROE

16.03 %

ROCE

21.27%

Profit Growth

-29.54 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 20 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-22.94%
3 Year0.5%
5 Year22.09%

Profit Growth

1 Year-29.54%
3 Year-0.42%
5 Year22.77%

ROE%

1 Year16.03%
3 Year28.55%
5 Year31.75%

ROCE %

1 Year21.27%
3 Year35.85%
5 Year38.59%

Debt/Equity

0.0188

Price to Cash Flow

72.67

Interest Cover Ratio

56.0419

CFO/PAT (5 Yr. Avg.)

0.971559048376076

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 50.10 0.00
Jun 2024 50.10 0.00
Mar 2024 50.10 0.00
Dec 2023 60.00 0.00
Sep 2023 60.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 30.5867 Cr.
  • Company has been maintaining healthy ROE of 28.5508511188353% over the past 3 years.
  • Company has been maintaining healthy ROCE of 35.8481840579725% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 56.0419.
  • The Company has been maintaining an effective average operating margins of 43.6928586629039% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 70.6698 days.
  • Company has a healthy liquidity position with current ratio of 6.4235.
  • The company has a high promoter holding of 50.1%.

 Limitations

  • The company has shown a poor profit growth of -0.415454095245549% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.501729439338128% for the Past 3 years.
  • The company is trading at a high PE of 108.96.
  • The company is trading at a high EV/EBITDA of 69.7807.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 224.62 212.83 243.52 222.09 236.06
Total Expenditure 126.58 144.69 171.38 139.05 135.05
Operating Profit 98.04 68.14 72.14 83.04 101.01
Other Income 14.2 13.97 16.87 17.95 13.43
Interest 1.14 1.27 2.29 1.6 1.47
Depreciation 10.53 11.33 15.67 12 12.29
Exceptional Items 0 0 0 0 0
Profit Before Tax 100.57 69.5 71.05 87.39 100.68
Tax 25.84 17.14 17.62 22.31 24.35
Profit After Tax 74.73 52.36 53.43 65.08 76.33
Adjusted EPS (Rs) 2.94 2.06 2.1 2.56 3

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 833.79 1009.72 1320.22 1330.08 1024.99
Total Expenditure 449 566.68 737.94 739.39 615.09
Operating Profit 384.79 443.04 582.28 590.69 409.9
Other Income 18.12 14.24 187.79 44.55 55.09
Interest 21.81 11.66 8.53 12.75 7.43
Depreciation 23.51 31.64 39.1 43.1 48.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 357.59 413.98 722.45 579.39 408.77
Tax 87.51 105.33 164.35 146.79 103.96
Net Profit 270.08 308.65 558.1 432.6 304.82
Adjusted EPS (Rs.) 10.61 12.12 21.92 16.99 11.97

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.73 25.46 25.46 25.46 25.46
Total Reserves 770.1 1039.73 1495.24 1723.92 2030.44
Borrowings 91.25 35.59 28.44 4.56 0
Other N/C liabilities 36.42 38.32 46.75 50.21 79.38
Current liabilities 319.85 321.49 346.23 298.5 203.58
Total Liabilities 1230.35 1460.59 1942.11 2102.65 2338.86
Assets
Net Block 356.74 441.16 534.19 512.03 523.54
Capital WIP 101.56 96.15 29.99 164.81 178.97
Intangible WIP 0.14 0.17 0 0 0.11
Investments 245.65 245.65 118.67 317.21 317.21
Loans & Advances 15.06 10.85 13.07 9.16 11.33
Other N/C Assets 0.2 0.16 0 0 0
Current Assets 511 666.45 1246.19 1099.44 1307.69
Total Assets 1230.35 1460.59 1942.11 2102.65 2338.86
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 357.59 413.98 722.45 579.39 408.77
Adjustment 33.35 36.48 -110.18 35.68 10.22
Changes in Assets & Liabilities 54.22 -12.19 -190.63 23.53 60.17
Tax Paid -86.41 -109.44 -151.74 -145.79 -108.52
Operating Cash Flow 358.75 328.84 269.89 492.82 370.65
Investing Cash Flow -366.65 -257.66 -90.29 -236.86 -381.58
Financing Cash Flow 8.57 -75.66 -156.48 -243.14 -13.78
Net Cash Flow 0.67 -4.49 23.12 12.81 -24.71

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 60.00 60.00 50.10 50.10 50.10
berhyanda limited 50.10 50.10 50.10 50.10 50.10
jasti property and equity... 9.90 9.90 - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 40.00 40.00 49.90 49.90 49.90
dsp healthcare fund - 3.83 - - 5.40
goldman sachs funds - gol... - - 1.11 1.16 1.19
hsbc small cap fund - - - - 1.13
invesco india manufacturi... - - - - 1.03
investor education and pr... 0.14 0.14 - - 0.14
jasti property and equity... - - - 9.90 9.90
sbi life insurance co. lt... - - - 1.10 1.91
tata nifty 500 multicap i... - - - - 1.02
uti small cap fund 3.86 3.95 - - 1.89
dsp value fund - - - 6.06 -
hsbc multi cap fund 1.48 - - 1.14 -
investor education and pr... - - 0.14 0.14 -
uti-unit linked insurance... - - 3.76 2.96 -
dsp equity savings fund 3.26 - 5.91 - -
hsbc midcap fund - 1.55 1.57 - -
jasti property and equity... - - 9.90 - -
amansa holdings private l... 2.38 2.38 - - -
tata flexi cap fund 1.15 - - - -

Ratings & Research Reports

Company Presentations

Company News

Suven Pharmaceuticals informs about investor presentation 15 Jan, 11:18 AM Suven Pharmaceuticals acquires 56% stake in NJ Bio 21 Dec, 6:01 PM Suven Pharmaceuticals to acquire controlling stake in NJ Bio 7 Dec, 5:29 PM Suven Pharmaceuticals informs about press release & investor presentation 7 Dec, 9:17 AM Suven Pharma - Quaterly Results 12 Nov, 6:25 PM Suven Pharma - Quaterly Results 12 Nov, 6:25 PM Suven Pharmaceuticals’ arm gets EIR from USFDA for manufacturing facility 9 Sep, 6:00 PM Suven Pharma - Quaterly Results 9 Aug, 3:34 PM Suven Pharma - Quaterly Results 9 Aug, 3:34 PM Suven Pharma - Quaterly Results 9 Aug, 3:34 PM Suven Pharmaceuticals informs about confirmation certificates 18 Jul, 2:30 PM USFDA completes surveillance inspection of Suven Pharmaceuticals’ arm 15 Jul, 10:12 AM Suven Pharmaceuticals informs about disclosures 19 Jun, 1:33 PM Suven Pharmaceuticals informs about disclosure 19 Jun, 12:45 PM Suven Pharmaceuticals informs about update on amalgamation 15 Jun, 3:41 PM Suven Pharma - Quaterly Results 30 May, 5:38 PM Suven Pharma - Quaterly Results 30 May, 5:38 PM Suven Pharma - Quaterly Results 30 May, 5:38 PM USFDA completes inspections at Suven Pharmaceuticals’ API, Formulations facilities 23 Feb, 5:15 PM Suven Pharma - Quaterly Results 5 Feb, 5:19 PM Suven Pharma - Quaterly Results 5 Feb, 5:19 PM Suven Pharma - Quaterly Results 5 Feb, 5:19 PM Suven Pharmaceuticals informs about disclosure 6 Dec, 2:46 PM Suven Pharmaceuticals informs about investor presentation 24 Nov, 5:24 PM Suven Pharma - Quaterly Results 9 Nov, 5:49 PM Suven Pharma - Quaterly Results 9 Nov, 5:49 PM Suven Pharmaceuticals informs about letter of offer 11 Oct, 2:50 PM Advent International completes acquisition of Suven Pharmaceuticals 30 Sep, 3:56 PM Suven Pharmaceuticals informs about transcript of conference call 14 Aug, 4:34 PM Suven Pharma - Quaterly Results 8 Aug, 4:14 PM Suven Pharma - Quaterly Results 8 Aug, 4:14 PM Suven Pharma - Quaterly Results 8 Aug, 4:14 PM Suven Pharmaceuticals informs about disclosure 12 Jun, 4:52 PM Suven Pharmaceuticals informs about earnings call transcript 2 Jun, 4:59 PM Suven Pharma - Quaterly Results 25 May, 1:41 PM Suven Pharma - Quaterly Results 25 May, 1:41 PM Suven Pharma - Quaterly Results 25 May, 1:41 PM CCI approves acquisition of up to 76.10% of voting share capital of Suven by Berhyanda 21 Apr, 10:00 AM Suven Pharmaceuticals informs about loss of share certificate 18 Mar, 12:21 PM Suven Pharma - Quaterly Results 6 Feb, 1:12 PM Suven Pharma - Quaterly Results 6 Feb, 1:12 PM Suven Pharma - Quaterly Results 6 Feb, 1:12 PM Suven Pharmaceuticals informs about conference call for investors 31 Jan, 11:40 AM Suven Pharmaceuticals informs about board meeting 30 Jan, 5:16 PM Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family 26 Dec, 9:42 AM Suven Pharmaceuticals informs about open offer 26 Dec, 9:26 AM Suven Pharmaceuticals informs about press release 26 Dec, 9:17 AM Suven Pharma - Quaterly Results 8 Nov, 12:42 PM Suven Pharma - Quaterly Results 8 Nov, 12:42 PM Suven Pharma - Quaterly Results 8 Nov, 12:42 PM

Suven Pharma Stock Price Analysis and Quick Research Report. Is Suven Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Suven Pharma and its performance over the period of time. Suven Pharma stock price today is Rs 1059.6.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Suven Pharma cash from the operating activity was Rs 370.6473 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Suven Pharma has a Debt to Equity ratio of 0.0188 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Suven Pharma , the EPS growth was -29.539 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Suven Pharma has OPM of 39.9904799368425 % which is a good sign for profitability.
     
  • ROE: Suven Pharma have a average ROE of 16.0291 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Suven Pharma is Rs 1059.6. One can use valuation calculators of ticker to know if Suven Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Suven Pharma
X